Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.42 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992641 | 0.88 | RECQL (0.52) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1991871 | 0.86 | L3MBTL1 (0.48) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1995091 | 0.85 | AKR1B1 (0.36) | SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL1998303 | 0.80 | RECQL (0.53) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1991515 | 0.78 | RECQL (0.55) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL5323230 | 0.76 | SMN1; SMN2 (0.73) | RECQLSMN1; SMN2ALDH1A1 | |
| SCHEMBL1998943 | 0.76 | RECQL (0.50) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1992765 | 0.74 | RECQL (0.56) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1996758 | 0.73 | RECQL (0.47) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1996755 | 0.73 | RECQL (0.47) | RECQLSMN1; SMN2ALDH1A1SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | RECQL 3604/4885SMN1; SMN2 2548/4885ALDH1A1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.